KNG1 Protein (Transcript Variant 2)

Catalog No. ABIN2724258

This Recombinant KNG1 protein is produced in HEK-293 Cells.

Quick Overview for KNG1 Protein (Transcript Variant 2) (ABIN2724258)

Target: KNG1 (Kininogen 1 (KNG1))

Protein Type: Recombinant

Origin: Human

Source: HEK-293 Cells

Application: Antibody Production (AbP), Standard (STD)

Purity: > 95 % as determined by SDS-PAGE and Coomassie blue staining

Product Details

Protein Characteristics: Transcript Variant 2

Characteristics:

• Recombinant human Kininogen-1 (transcript variant 2) protein expressed in HEK293 cells.
• Produced with end-sequenced ORF clone

Endotoxin Level: < 0.1 EU per μg protein as determined by LAL test

Application Details

Application Notes: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Restrictions: For Research Use only

Handling

Buffer: Lyophilized from a 0.2 μM filtered solution of 20 mM Hac-NaAC, 150 mM NaCl, pH 4.0. Stable for at least 6 months from date of receipt under proper storage and handling conditions.

Storage: -80 °C

Storage Comment: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Target Details

Target: KNG1 (Kininogen 1 (KNG1))

Alternative Name: Kininogen-1

Background: (1) Kininogens are inhibitors of thiol proteases (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action) (5) LMW-kininogen inhibits the aggregation of thrombocytes (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. [UniProtKB/Swiss-Prot Function]

Molecular Weight: 46.9 kDa

NCBI Accession: NP_000884

Pathways: ACE Inhibitor Pathway, Glycosaminoglycan Metabolic Process